Jubilant Pharmova

USFDA Flags Jubilant Facility as VAI Post Inspection

USFDA classified Jubilant Pharmova's Spokane facility as VAI after June 2026 inspection. VAI indicates issues found but voluntary corrective actions are planned by the company. Source: ScoutQuest

Jubilant Pharmova: Gets ₹87.31 Crore GST Notice From Mysore Tax Authorities For FY23.

Jubilant Pharmova Gets ₹33.6 Cr GST Demand, Contests Notice

Jubilant Pharmova faces GST demand of Rs. 33.6 Cr for FY23. Interest Rs. 20.2 Cr, penalty Rs. 33.6 Cr; firm contests notice. Source: ScoutQuest

Jubilant Generics Gets ₹105.5 Cr CGST Notice for Rule Violations

Jubilant Generics faces Rs 105.5 cr notice from Uttarakhand CGST authority. The notice alleges rule violations during FY 2020-21 and 2021-22. Source: The Economic Times

Jubilant Pharmova Hit with ₹52.75 Cr IGST Refund Demand

Jubilant Pharmova faces ₹52.75 crore demand for ineligible IGST refund. Notice issued by Joint Commissioner, CGST Division, Roorkee. Source: Livesquawk

Jubilant Pharmova: Gets Notice From Joint Commissioner, CGST Division, Roorkee, Proposing ₹52.75 Crore Demand For Ineligible IGST Refund.

USFDA Observations Hit Caplin, Natco; Jubilant Gains on New Approval

USFDA issued 10 observations to Caplin Point, 4 to Natco Pharma, and 1 to Aurobindo Pharma post inspections. Jubilant Pharmova's US arm received approval for a new product line. Shares of all 4 pharma firms saw varied movements. Source: CNBC TV 18

Jubilant Pharmova: Company Gets USFDA Green Light for New Isolator Fill and Finish Line at Spokane Facility.

Jubilant Pharmova Gains USFDA Nod for Line 3, Boosting Production

Jubilant Pharmova's Spokane facility secures USFDA approval for Line 3, enabling commercial production. Jubilant Pharmova shares traded at Rs. 879.15, with intraday high of Rs. 890 and turnover of Rs. 1.02 crore. Source: Equity Bulls

Jubilant Pharmova Gains USFDA Nod for Spokane Facility

Jubilant Pharmova gets USFDA nod for new fill-finish line at Spokane. Source: ScoutQuest